bodyType

customContents

entityId

entityUuid

articlePageQuery

filter

article

articleBaseAdvertisingInfoArticle

articleListArticle

articleSeoArticle

helpersCheckIsPostiesArticle

hooksArticleAcknowledgementGateOverlayArticle

hooksTrackPageViewArticle

hooksContentInterestArticle

articleLinkingDataContent

articleSchemaContent

liveArticle

advertZone

sentiment

contentLock

topics

types

sections

moreOnThisArticles

urlAlias

commentCount

authorLocations

authors

paywallTypes

corrections

sponsorType

displaySlideShow

multimediaEmbed

printHeadline

seriesContainer

socialHeadline

headline

flag

firstTopic

glossary

flattenTypeIds

publishedDate

additionalInfoBoxes

images

image

relatedLinks

relatedNewsletters

__typename

createdDate

sponsor

factSheets

seriesReverseOrder

series

disableOffPlatformContent

published

updatedDate

summary

subHeadline

body

keywords

copyrighted

customTimezone

liveContents

Eric Ng

Hong Kong’s cancer DNA tests industry has received a shot in the arm from Taiwan-based ACT Genomics opening a HK$20 million laboratory at the Science Park in Sha Tin to process cancer patients’ samples.
The five-year-old firm, based in Taipei, aims to build a regional network of self-operated and joint venture labs.
“We want to become Asia’s most important DNA tests provider [for cancer patients],” ACT’s chief executive Chen Hua-chien told reporters on Thursday after the lab’s opening ceremony. “We plan to achieve this by setting up our own labs as well as forming partnerships in markets that are difficult to enter.”
More nations in Asia are expected to tighten regulations that will make exporting DNA materials for testing overseas more burdensome and less efficient, he noted.
Hong Kong gene testing companies under probe after ‘exaggerated’ claims
In one such market, Japan, ACT has formed a partnership with Canon Medical System – a medical imaging unit of optical equipment giant Canon – to open a lab.
In mainland China, where the collection of DNA samples by foreign firms is banned and the export of human DNA material is restricted to scientific research, ACT is in talks with potential partners.
ACT has performed DNA tests on over 7,000 cancer cases in Asia, including around 450 in Hong Kong.
The costs range from US$1,000 to over US$4,000 each, depending on the number of genes being profiled.

The firm is trying to convince private insurers in Taiwan and Hong Kong to provide the tests to their clients as part of their coverage. Both places’ public health insurance schemes do not cover such tests.
“The tests’ costs are a fraction of the costs of treatments, but could potentially make big improvements to treatment outcomes and reduce costs,” Chen said.
Its rivals include Hong Kong’s Sanomics, backed by conglomerate New World Development’s parent Chow Tai Fook Enterprises and Shenzhen-based Berry Genomics, besides Singapore’s Lucence Diagnostics.
Prenetics is first in Hong Kong to take cancer risk DNA test direct to consumers
Since inception, ACT has raised US$50 million from investors.
Shareholders include Hong Kong Science & Technology Park’s corporate venture fund, Japanese venture capital firm Jafco, Asia-focused investment firm CLSA, Singapore’s UOB Venture Management, Taiwan financial institutions and wealthy individuals in Taiwan and Hong Kong.
Chief financial officer Victor Chan said the company is in talks to raise another round of private funding ahead of a potential initial public offering in Hong Kong. He declined to give a time frame.
York Chow Yat-ngok, an orthopaedic surgeon and a former Secretary for Food and Health in Hong Kong, said hundreds companies globally offer DNA tests to assess healthy people’s cancer risks, but post-diagnostic DNA test providers are far less numerous.
“The former can tell if people’s DNA make-up means they are more prone to developing certain types of cancers some time in their life, but such tests often raise questions that cannot be answered, such as what to do next,” he said.
Post-diagnostic tests profile the genetic make-up of people already diagnosed with cancers, to help identify the treatment most effective for them.
“More importantly, they can tell which treatment options are not effective so that time and resources will not be wasted,” he added.


Genetic links to depression found in big global study, giving hope for new treatments

Does castor oil improve health? It’s a social media hit and was used by Cleopatra

Why acupuncture attracts growing numbers of people for its pain relief and other effects

Cooperation best on flu jabs for Hong Kong’s children

Medicine

Hong Kong’s cancer DNA tests industry gets a boost as Taiwanese provider ACT Genomics opens lab

ACT is in talks with potential partners in mainland China, where the collection of DNA samples by foreign firms is banned. Photo: Shutterstock

Dr Chen Hua Chien, chief executive officer at ACT Genomics, at the new Hong Kong laboratory at the science park in Sha Tin. Photo: Dickson Lee

Temasek unit-backed firm Lucence to tap Hong Kong cancer screening market

The Lucence liquid biopsy test costs more than US$1,000, which represents just 10 per cent to 20 per cent of the cost of a tissue biopsy, according to its founder. Photo: Shutterstock

Chief Executive Officer & Medical Director of Lucence Diagnostics, Tan Min-han photographed in Tai Koo. 24APR19 SCMP / Xiaomei Chen

Hong Kong could become a hub for genetics-based drugs discovery. Just one hitch – would Beijing stand in way?

Stanley Sy, CEO and director of Sanomics, demonstrates an experiment at the Hong Kong Science Park in Sha Tin. Photo: Dickson Lee

Prenetics is first Hong Kong firm to take genetic test kit for cancer risk direct to consumers

Danny Yeung Sheng-wu, CEO and co-founder of Prenetics, displays a biochip in the company’s laboratory for genetic testing in Quarry Bay, Hong Kong. Photo: Nora Tam

Hong Kong genes testing start-up Prenetics buys UK peer DNAFit to broaden consumer reach 

Prenetics partners with insurers to provide genetic profiling to help people tailor their diets and assess the risk of hereditary cancers. Photo: Shutterstock

Danny Yeung Sheng-wu, CEO of Groupon, poses for photographers at his office in Wan Chai. 04MAR2011

Why DNA testing kit makers are investing in China

China’s DNA sequencing market is expected to grow to 18.3b yuan by 2022 from 7.2b yuan last year, much faster than the overall global market because of rising income and growing investments in health care infrastructure, studies show

Zhou Wei, chief executive of DNA testing semiconductor maker Centrillion Technologies, is upbeat on the company’s prospects in China. Photo: Handout

Business

Companies

Tech

Enterprises

Innovation

Science & Research

Taiwan-based ACT Genomics opens a HK$20 million laboratory at the Science Park in Sha Tin to process cancer patients’ samples
The five-year-old firm, based in Taipei, aims to build a regional network of self-operated and joint venture labs


Taiwan-based ACT Genomics opens a HK$20 million laboratory at the Science Park in Sha Tin to process cancer patients’ samples


Wellness

Hong Kong’s cancer DNA tests industry gets a boost as Taiwanese provider ACT Genomics opens lab

Taiwan-based ACT Genomics opens a HK$20 million laboratory at the Science Park in Sha Tin to process cancer patients’ samples The five-year-old firm, based in Taipei, aims to build a regional network of self-operated and joint venture labs

Taiwan-based ACT Genomics opens a HK$20 million laboratory at the Science Park in Sha Tin to process cancer patients’ samples

The five-year-old firm, based in Taipei, aims to build a regional network of self-operated and joint venture labs